8-K: Vivos Therapeutics Secures $850K Via Private Placement

Vivos Therapeutics, Inc. announced the closing of a private placement offering, raising $850,000 in cash and converting $1.4 million from a bridge note, to be used for general working capital.

Summary

• Vivos Therapeutics, Inc. has closed a private placement offering (PIPE Offering) with V-Co Investors 3 LLC, an affiliate of New Seneca Partners Inc.
• The offering raised $850,000 in cash and converted $1.4 million from a previously issued bridge promissory note.
• The company sold 1,353,625 shares of Common Stock, a pre-funded warrant, a Series A warrant, and a Series B warrant.
• The purchase price was $1.34 per unit, with the cash proceeds intended for general working capital.
• The Series A warrant expires in two years, and the Series B warrant expires in five years, both with an exercise price of $1.09 per share.
• The pre-funded warrant has a nominal exercise price of $0.0001 and no expiration date, effectively representing immediate stock ownership.
• The company is obligated to file a resale registration statement within 45 days and have it effective within 90 days, maintained for three years.
• Anti-dilution protection and a beneficial ownership limitation of 19.99% are included in the warrants.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it provides necessary capital but also introduces potential dilution for existing shareholders.

Positives

• Secured $850,000 in new cash proceeds.
• Successfully converted $1.4 million from a bridge note, strengthening the balance sheet.
• The pre-funded warrant provides immediate equity-like characteristics without further cash outlay for the holder.
• The company has a clear path to register the securities for resale, facilitating liquidity for investors.
• Warrants include anti-dilution protection, safeguarding against future equity dilution.

Negatives

• The company is issuing a significant number of shares and warrants, which could lead to substantial dilution for existing shareholders upon exercise.
• The need for a resale registration statement indicates that the securities were issued in a private placement and are not freely tradable.
• The company is obligated to pay $50,000 for V-Co 3's counsel fees.

Risks

• Potential for significant dilution to existing shareholders if warrants are exercised.
• The company's reliance on private placements and bridge notes suggests potential ongoing capital needs.
• The effectiveness of the resale registration statement is crucial for investor liquidity and is subject to SEC review.
• The beneficial ownership limitation of 19.99% could restrict the ability of V-Co 3 or its affiliates to fully exercise their warrants if the company's outstanding shares are low.

Future Outlook

The company intends to use the net proceeds for general working capital. A key future step is the filing and effectiveness of a resale registration statement for the issued securities.

Industry Context

StockSavvy.ai notes that this type of private placement financing, often referred to as a PIPE (Private Investment in Public Equity), is a common method for public companies, particularly those in development or growth stages, to raise capital quickly. The inclusion of warrants is standard practice to enhance the attractiveness of the offering to investors.

Comparison to Industry Standards

• The purchase price of $1.34 per unit is within the typical range for PIPE offerings, especially when considering the inclusion of multiple warrants and a pre-funded warrant.
• The exercise price of $1.09 for the common stock purchase warrants is below the offering price, which is common to incentivize exercise.
• The commitment to file a resale registration statement within 90 days and maintain its effectiveness for three years aligns with typical investor expectations for liquidity in such transactions.

Related Party Transactions

• V-Co Investors 3 LLC is an affiliate of New Seneca Partners Inc., an existing sponsor and private equity firm involved with Vivos Therapeutics.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new shares and warrants.
• Investors (V-Co 3): Gain equity and potential upside through warrants, with registration rights for liquidity.
• Creditors: The capital infusion may improve the company's ability to meet its financial obligations.

Next Steps

• File a resale registration statement on Form S-3 (or other appropriate form) within 45 days of the closing.
• Use commercially reasonable best efforts to cause the Resale Registration Statement to be effective within 90 days of the closing.
• Keep the Resale Registration Statement continuously effective for three years after effectiveness, subject to limitations.
• Use net proceeds for general working capital purposes.

Key Dates

Recommendation

The financing provides essential working capital and a path to liquidity for investors, but the significant potential for dilution upon warrant exercise warrants a cautious 'hold' stance until the company demonstrates sustained operational progress and revenue growth.

Keywords

Vivos Therapeutics, PIPE Offering, Securities Purchase Agreement, Warrants, Pre-funded Warrant, Common Stock, Private Placement, Registration Statement